Parsol 1789
This article was originally published in The Rose Sheet
Executive Summary
Canadian Dermatology Association writes FDA to support the inclusion of Givaudan-Roure's Parsol 1789 in the sunscreen final monograph. R. W. Danby, MD, chair of CDA's Sunscreen Product Education Program, states that since the UVA ingredient's Canadian approval in 1989, "there have been a relatively small number of cases of allergic sensitization" to products including Parsol 1789, with "only two cases" of adverse reactions to Parsol 1789- containing sunscreens being reported. CDA's cutaneous adverse reaction program "confirms the lack of significant" adverse events reporting, he said. Danby noted that the reference patch test clinic in Ottawa reported only "about seven" patch test positive cases and that it "sees significantly more reactions to oxybenzone and other benzophenones"